AHFS Class:

10:00 Antineoplastic Agents

Generic Name

• Amivantamab (CAS Registry Number: 2171511-58-1)

Amivantamab-vmjw is available as a 50-mg/mL concentrate for injection in 7-mL preservative-free single-dose vials.³⁹⁹² Each vial contains amivantamab-vmjw 350 mg with edetate disodium (EDTA) dihydrate 0.14 mg, L-histidine 2.3 mg, L-histidine hydrochloride monohydrate 8.6 mg, L-methionine 7 mg, polysorbate 80 4.2 mg, and sucrose 595 mg in water for injection.³⁹⁹²

To prepare a diluted solution for administration, a volume of compatible diluent (dextrose 5% or sodium chloride 0.9%) equivalent to the volume of the concentrate for injection to be added should be removed from a 250-mL infusion bag before transferring the appropriate volume of amivantamab-vmjw concentrate for injection to the infusion bag.³⁹⁹² The manufacturer states only infusion bags composed of PVC, polypropylene, polyethylene, or polyolefin blend should be used.³⁹⁹² The diluted solution should be mixed by gentle inversion; do not shake.³⁹⁹²

pH

Concentrate for injection: 5.7.³⁹⁹²

Trade Name(s)

Rybrevant

Amivantamab-vmjw is administered by intravenous infusion following dilution.³⁹⁹² An infusion set fitted with a flow regulator and with an inline 0.2-µm low protein-binding polyethersulfone filter primed with diluent only should be used.³⁹⁹² During treatment weeks 1 and 2, the infusion should be administered through a peripheral line because of the risk of infusion-related reactions.³⁹⁹²

Infusion rates depend on the dose and treatment schedule; specific product labeling should be consulted.³⁹⁹²

Intact vials should be stored at 2 to 8°C in the original carton to protect from light.³⁹⁹² Do not freeze.³⁹⁹²

Amivantamab-vmjw concentrate for injection is a colorless to pale yellow solution; do not use if the solution is discolored or contains particulate matter.³⁹⁹²

The manufacturer states diluted solutions should be administered within 10 hours at room temperature, including administration time.³⁹⁹² For the initial infusion, it is recommended to prepare the diluted solution as close to administration time as possible to allow for extended infusion time in the event of an infusion-related reaction.³⁹⁹²

Sorption

Manufacturer states final diluted solution for infusion should be prepared in infusion bags composed of PVC, polypropylene, polyethylene, or polyolefin blend (polypropylene/polyethylene).³⁹⁹² Administration sets must be composed of either polyurethane, polybutadiene, PVC, polypropylene, or polyethylene.³⁹⁹²

Filtration

Diluted solutions for infusion should be administered through an inline 0.2-µm low protein-binding polyethersulfone filter.³⁹⁹²

Solution Compatibility

For a list of references cited in the text of this monograph, search the monograph titled References.

ASHP^® Injectable Drug Information^TM. Selected Revisions December 5, 2024. © Copyright, 2025. American Society of Health-System Pharmacists^®, 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.